Title of article
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Author/Authors
Craig L Leonardi، نويسنده , , Alexa B. Kimball، نويسنده , , Kim A. Papp، نويسنده , , Newman Yeilding، نويسنده , , Cynthia Guzzo، نويسنده , , Yuhua Wang، نويسنده , , Shu Li، نويسنده , , Lisa T Dooley، نويسنده , , Kenneth B Gordon ، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
10
From page
1665
To page
1674
Abstract
Background
Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We assessed ustekinumab, a human monoclonal antibody directed against these cytokines, for the treatment of psoriasis.
Methods
In this phase III, parallel, double-
Journal title
The Lancet
Serial Year
2008
Journal title
The Lancet
Record number
592890
Link To Document